A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. (Q42544672)
Jump to navigation
Jump to search
scientific article published on February 1998
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. |
scientific article published on February 1998 |
Statements
1 reference
A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. (English)
1 reference
Balzarini J
1 reference
Pelemans H
1 reference
Esnouf R
1 reference
De Clercq E
1 reference
1 February 1998
1 reference
1 reference
Identifiers
1 reference